Immuno-oncology
Feature
CMS proposes payment increase for administering CAR T in the hospital
The CMS would raise the new technology add-on payment to hospitals for administration of CAR T-cell therapies from $186,500 to $242,450.
Conference Coverage
Myc signaling, monocytes predict NSCLC response to second-line entinostat + pembro
ATLANTA – Investigators have identified factors associated with response to combination entinostat and pembrolizumab among NSCLC patients who...
Conference Coverage
SRA737 + anti–PD-L1 therapy and low-dose gemcitabine shows early promise for SCLC
ATLANTA – Preclinical data suggest a role for SRA737 plus anti–PD-L1 therapy and low-dose gemcitabine in SCLC.
Conference Coverage
High pCR rate in HPV+ HNSCC with nivolumab/SBRT
ATLANTA – Nine of 10 patients in a phase 1/1b trial had pathologic complete responses to neoadjuvant nivolumab and radiation.
Conference Coverage
MYSTIC trial: bTMB correlates with tTMB, predicts survival in mNSCLC
ATLANTA – Blood TMB predicts survival benefit in mNSCLC patients treated with first-line durvalumab plus tremelimumab versus chemo, according to...
Feature
ICYMI: NIH renames, streamlines gene therapy committee
The Recombinant DNA Advisory Committee will now be known as the Novel and Exceptional Technology and Research Advisory Committee.
How I will treat my next patient
Lessons from KEYNOTE-158 and the role of R-CHOP
Dr. Alan P. Lyss breaks down the clinical relevance of two recent studies in advanced cervical cancer and diffuse large B-cell lymphoma.
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
Conference Coverage
PACIFIC: Patient-reported outcomes unaffected by PD-L1 expression
GENEVA – Level of programmed death-ligand 1 expression does not impact patient-reported outcomes among those...
Conference Coverage
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
Conference Coverage
ENCORE-601: Entinostat/pembrolizumab safe, active for melanoma
ATLANTA – Combined therapy with the HDAC inhibitor entinostat and the PD-1 inhibitor pembrolizumab has significant clinical activity and...